Failure museum
Oncology learns more from what did not work than from what did, but failures vanish from pipelines and press releases. This room keeps them: drugs stopped, targets abandoned, approvals withdrawn, each with the lesson it left. Nothing here is a verdict on the idea; several of these targets later worked with a different weapon.
Why failures are shown: they are how the field learns. Every drug that did not work sharpened the next one: a target that survived a bad molecule, a dose that was wrong, a trial design that misled. Several targets in this room later worked with a different weapon, and the lesson attached to each exhibit is what the successful drugs were built on. Nothing here is a statement about any patient's outlook; it is the field's record of what it tried, kept so it does not have to be learned twice.
Other setbacks
Negative or withdrawn items without a single dominant lesson.
Aducanumab was an amyloid antibody whose US Alzheimer’s indication was later withdrawn. It is historical context, not a current option.
ENGAGE was a phase 3 aducanumab trial that did not meet its primary endpoint as designed. It is here as a failure, not as support for using the drug.
EXPEDITION 3 tested solanezumab in mild Alzheimer’s disease and did not meet its primary endpoint. It is included as a negative amyloid-antibody result.